ID: ALA3763674

Max Phase: Preclinical

Molecular Formula: C26H23FN4O

Molecular Weight: 426.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=c1[nH]nc2c3c(cccc13)NC(c1ccc(CN3CCC3)cc1)C2c1ccc(F)cc1

Standard InChI:  InChI=1S/C26H23FN4O/c27-19-11-9-17(10-12-19)22-24(18-7-5-16(6-8-18)15-31-13-2-14-31)28-21-4-1-3-20-23(21)25(22)29-30-26(20)32/h1,3-12,22,24,28H,2,13-15H2,(H,30,32)

Standard InChI Key:  UMTZOWPWZLHANK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 426.50

Molecular Weight (Monoisotopic): 426.1856

AlogP: 4.57

#Rotatable Bonds: 4

Polar Surface Area: 61.02

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.06

CX Basic pKa: 8.35

CX LogP: 3.56

CX LogD: 2.68

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.50

Np Likeness Score: -1.09

References

1. Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE..  (2016)  Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.,  59  (1): [PMID:26652717] [10.1021/acs.jmedchem.5b01498]

Source

Source(1):

• Scientific Literature